Inizio Uno

Inizio is a leading global consulting firm providing strategic advisory and commercialization services for life sciences companies at every stage of product development, from discovery through post-launch. Formed in 2022 by the merger of Ashfield and Huntsworth under private equity ownership by Clayton Dubilier & Rice, it supports clients across all modalities and indications, including over 60% of top 20 pharma launches and more than 100 biotech firms globally. It operates through specialist divisions covering areas like medical affairs communications, market access, patient engagement, creative marketing, real-world evidence generation, and pricing strategy. As a service provider, Inizio does not develop drugs, maintain its own R&D pipeline, or produce clinical results, but partners with innovators to maximize asset value.